Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions

Sridhar Mani, Mohammed Ghalib, Imran Chaudhary, Sanjay Goel

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Drug interactions in oncology are common place and largely ignored as we tolerate high thresholds of 'toxic' drug responses in these patients. However, in the era of 'targeted' or seemingly 'less toxic' therapy, these interactions are more commonly flagged and contribute significantly towards poor 'quality of life' and medical fatalities. Objective: This review and opinion article focuses on alteration of chemotherapeutic pharmacokinetic profiles by drug interactions in the setting of polypharmacy. The assumption is that the drugs, with changes in their pharmacokinetics, will contribute towards changes in their pharmacodynamics. Methods: The examples cited for such drug-drug interactions are culled from published literature with an emphasis on those interactions that have been well characterized at the molecular level. Results: Although very few drug interaction studies have been performed on approved oncology based drugs, it is clear that drugs whose pharmacokinetics profiles are closely related to their pharmacodynamics will indeed result in clinically important drug interactions. Some newer mechanisms are described that involve interactions at the level of gene transcription, whereby, drug metabolism is significantly altered. However, for any given drug interaction, there does not seem to be a comprehensive model describing interactions. Conclusions: Mechanisms based drug interactions are plentiful in oncology; however, there is an absolute lack of a comprehensive model that would predict drug-drug interactions.

Original languageEnglish (US)
Pages (from-to)109-130
Number of pages22
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume5
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Drug interactions
Pharmacokinetics
Drug Interactions
Pharmaceutical Preparations
Oncology
Pharmacodynamics
Poisons
Polypharmacy
Transcription
Metabolism
Genes
Quality of Life

Keywords

  • Drug metabolism
  • Orphan nuclear receptors
  • Pharmacokinetic-pharmacodynamic relationships
  • Pregnane X receptor
  • Transcriptional regulation

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions. / Mani, Sridhar; Ghalib, Mohammed; Chaudhary, Imran; Goel, Sanjay.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, No. 2, 02.2009, p. 109-130.

Research output: Contribution to journalArticle

@article{823e92ccd1b741a19d40b68299189cd6,
title = "Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions",
abstract = "Background: Drug interactions in oncology are common place and largely ignored as we tolerate high thresholds of 'toxic' drug responses in these patients. However, in the era of 'targeted' or seemingly 'less toxic' therapy, these interactions are more commonly flagged and contribute significantly towards poor 'quality of life' and medical fatalities. Objective: This review and opinion article focuses on alteration of chemotherapeutic pharmacokinetic profiles by drug interactions in the setting of polypharmacy. The assumption is that the drugs, with changes in their pharmacokinetics, will contribute towards changes in their pharmacodynamics. Methods: The examples cited for such drug-drug interactions are culled from published literature with an emphasis on those interactions that have been well characterized at the molecular level. Results: Although very few drug interaction studies have been performed on approved oncology based drugs, it is clear that drugs whose pharmacokinetics profiles are closely related to their pharmacodynamics will indeed result in clinically important drug interactions. Some newer mechanisms are described that involve interactions at the level of gene transcription, whereby, drug metabolism is significantly altered. However, for any given drug interaction, there does not seem to be a comprehensive model describing interactions. Conclusions: Mechanisms based drug interactions are plentiful in oncology; however, there is an absolute lack of a comprehensive model that would predict drug-drug interactions.",
keywords = "Drug metabolism, Orphan nuclear receptors, Pharmacokinetic-pharmacodynamic relationships, Pregnane X receptor, Transcriptional regulation",
author = "Sridhar Mani and Mohammed Ghalib and Imran Chaudhary and Sanjay Goel",
year = "2009",
month = "2",
doi = "10.1517/17425250902753212",
language = "English (US)",
volume = "5",
pages = "109--130",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions

AU - Mani, Sridhar

AU - Ghalib, Mohammed

AU - Chaudhary, Imran

AU - Goel, Sanjay

PY - 2009/2

Y1 - 2009/2

N2 - Background: Drug interactions in oncology are common place and largely ignored as we tolerate high thresholds of 'toxic' drug responses in these patients. However, in the era of 'targeted' or seemingly 'less toxic' therapy, these interactions are more commonly flagged and contribute significantly towards poor 'quality of life' and medical fatalities. Objective: This review and opinion article focuses on alteration of chemotherapeutic pharmacokinetic profiles by drug interactions in the setting of polypharmacy. The assumption is that the drugs, with changes in their pharmacokinetics, will contribute towards changes in their pharmacodynamics. Methods: The examples cited for such drug-drug interactions are culled from published literature with an emphasis on those interactions that have been well characterized at the molecular level. Results: Although very few drug interaction studies have been performed on approved oncology based drugs, it is clear that drugs whose pharmacokinetics profiles are closely related to their pharmacodynamics will indeed result in clinically important drug interactions. Some newer mechanisms are described that involve interactions at the level of gene transcription, whereby, drug metabolism is significantly altered. However, for any given drug interaction, there does not seem to be a comprehensive model describing interactions. Conclusions: Mechanisms based drug interactions are plentiful in oncology; however, there is an absolute lack of a comprehensive model that would predict drug-drug interactions.

AB - Background: Drug interactions in oncology are common place and largely ignored as we tolerate high thresholds of 'toxic' drug responses in these patients. However, in the era of 'targeted' or seemingly 'less toxic' therapy, these interactions are more commonly flagged and contribute significantly towards poor 'quality of life' and medical fatalities. Objective: This review and opinion article focuses on alteration of chemotherapeutic pharmacokinetic profiles by drug interactions in the setting of polypharmacy. The assumption is that the drugs, with changes in their pharmacokinetics, will contribute towards changes in their pharmacodynamics. Methods: The examples cited for such drug-drug interactions are culled from published literature with an emphasis on those interactions that have been well characterized at the molecular level. Results: Although very few drug interaction studies have been performed on approved oncology based drugs, it is clear that drugs whose pharmacokinetics profiles are closely related to their pharmacodynamics will indeed result in clinically important drug interactions. Some newer mechanisms are described that involve interactions at the level of gene transcription, whereby, drug metabolism is significantly altered. However, for any given drug interaction, there does not seem to be a comprehensive model describing interactions. Conclusions: Mechanisms based drug interactions are plentiful in oncology; however, there is an absolute lack of a comprehensive model that would predict drug-drug interactions.

KW - Drug metabolism

KW - Orphan nuclear receptors

KW - Pharmacokinetic-pharmacodynamic relationships

KW - Pregnane X receptor

KW - Transcriptional regulation

UR - http://www.scopus.com/inward/record.url?scp=67649133610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649133610&partnerID=8YFLogxK

U2 - 10.1517/17425250902753212

DO - 10.1517/17425250902753212

M3 - Article

C2 - 19239394

AN - SCOPUS:67649133610

VL - 5

SP - 109

EP - 130

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 2

ER -